JAKAFI® (ruxolitinib) delivered high and durable response rates vs BAT, which included ECP and Imbruvica® (ibrutinib)1,2*

REACH3 primary endpoint: ORR through week 24

70% (116/165) with JAKAFI vs 57% (94/164) with BAT2

  • In the JAKAFI Prescribing Information, efficacy was based on ORR through week 24 (cycle 7, day 1)2
 
 
49.7%
ORR at Week 24 in a Study of JAKAFI and BAT1

Limitation: REACH3 was not powered to compare ORR for JAKAFI to individual BATs

Image
REACH3 ORRs at Week 24 chart
74% of patients on BAT received ECP, MMF, or ibrutinib1† 

Secondary endpoint: duration of response (DOR)

Patients treated with JAKAFI maintained a response at 12 months and 36 months vs BAT (DOR probability: 70.2% and 59.6%, respectively)1,3,4

  • Median DOR was 4.2 months with JAKAFI (95% CI, 3.2–6.7) vs 2.1 months with BAT (95% CI, 1.6–3.2)2
  • At 3-year follow-up, median DOR for JAKAFI was not estimable vs BAT (6.4 months)3
59.6%
Probability of Maintaining Response at 36 Months With JAKAFI and 26.7% Probability With BAT3,4
Image
Chart showing higher 36‑month response rate with Jakafi (59.6%) compared with BAT (26.7%).

If I don’t see a response within 7 days, I initiate a second-line treatment, with JAKAFI being my preferred choice.”

Haris Ali, MD, GVHD Expert

Dr Haris Ali, MD, GVHD Expert

Patients treated with JAKAFI were

3×

more likely to achieve an overall response at week 24 vs BAT (OR, 2.99)1

Median time to first response

3

weeks (range: 2-24) with JAKAFI and 4 weeks (range: 2-25) with BAT2

  • 74% of patients treated with BAT received ECP, MMF, or ibrutinib; ORR at week 24 was1,5‡§:
    • ECP: 29.1% (16/55; CR, 1.8%; PR, 27.3%), MMF: 28.6% (10/35; CR, 2.9%; PR, 25.7%), ibrutinib: 22.2% (6/27; CR, 7.4%; PR, 14.8%)

*DOR was defined as the time from first response until cGVHD progression, death, or the date of change/addition of systemic therapies for cGVHD.3

†BAT was chosen by the investigator at the time of randomization.1

‡The 74% value is based on the number of patients treated with BAT (n=158). ORRs for the remaining BATs were 20% (1/5) for everolimus, 25% (2/8) for imatinib, 20% (1/5) for infliximab, 30% (3/10) for low-dose MTX, 16.7% (1/6) for rituximab, and 28.6% (2/7) for sirolimus.1,5

§REACH3 was not powered to compare ORR for JAKAFI to individual BATs.

Study design

REACH31,2

REACH study design chart comparing ruxolitinib and BAT treatment groups in SR cGVHD patients
REACH study design chart comparing ruxolitinib and BAT treatment groups in SR cGVHD patients

aCrossover from BAT to JAKAFI was permitted on or after week 24 if patients progressed, had a mixed or unchanged response, developed toxicity to BAT, or experienced a cGVHD flare. 61 patients crossed over to JAKAFI after week 24. 72% of those who crossed over remained on JAKAFI longer than 24 weeks.1,3

bBAT was chosen by the investigator prior to randomization: Options included ibrutinib, ECP, low-dose MTX, MMF, rituximab, everolimus, sirolimus, imatinib, infliximab, and pentostatin.2

cDefined as the proportion of patients with CR or PR at week 24.1

  • Inclusion criteria1*
    • Age 12 and older
    • Allogeneic stem cell transplant from any donor source and donor type
    • SR/SD cGVHD per NIH consensus criteria (moderate or severe)
    • Evident myeloid and platelet engraftment
  • In the JAKAFI Prescribing Information, efficacy was based on ORR through week 24 (cycle 7, day 1)2

*Organ involvement at baseline for all patients (N=329): skin (71.1%), mouth (60.8%), eyes (57.4%), lungs (42.9%), joints and fascia (27.4%), liver (24.9%), GI tract (22.8%), genital tract (9.4%), missing (0.3%). Organ involvement was based on NIH consensus staging criteria at screening. A score of ≥1 was counted as organ involvement. Patients with missing assessments of single organs were counted as having no organ involvement for the organ assessed.1

BAT=best available therapy; BID=twice daily; cGVHD=chronic graft-versus-host disease; CNI=calcineurin inhibitor; CR=complete response; ECP=extracorporeal photopheresis; GI=gastrointestinal; MMF=mycophenolate mofetil; MTX=methotrexate; NIH=National Institutes of Health; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SD=steroid dependent; SR=steroid refractory.

Post Hoc Analysis: Overall Response at Week 24 by Time-to-Treat Initiation From SR Diagnosis6

Limitations: Post hoc analysis was not powered for statistical significance and results should be interpreted with caution.

No significant differences were observed between ruxolitinib time-to-treatment subgroups for ORR, BOR, or DOR.6

Bar chart showing higher week 24 overall response with Jakafi vs BAT across early and late treatment initiation groups

My experience has taught me the importance of early intervention on second-line therapy. This is supported by the REACH3 data."

Haris Ali, MD, GVHD Expert

Dr Haris Ali, MD, GVHD Expert

REACH3 Subgroup Analysis: ORR at Week 24 by Baseline Organ Involvement1,a

Limitations: This was a prespecified secondary endpoint that was not powered for statistical significance and is therefore considered exploratory.

Subgroup analyses have an increased risk of false positives due to multiple testing and may have reduced statistical power in smaller subgroups.

Response across organs chart
Response across organs chart

aPatients with >1 affected organ were counted in each organ subgroup. Organ involvement was defined as organ score ≥1 based on the cGVHD staging criteria.1

Dr Preet M. Chaudhary

Seeing that JAKAFI is effective gives us the confidence to initiate JAKAFI at early changes in skin disease to really get the opportunity to help control cGVHD.”

Preet M. Chaudhary, MD, PhD, GVHD Expert

BAT=best available therapy; BOR=best overall response; cGVHD=chronic graft-versus-host disease; CI=confidence interval; CR=complete response; ECP=extracorporeal photopheresis; GI=gastrointestinal; MMF=mycophenolate mofetil; MTX=methotrexate; NIH=National Institutes of Health; OR=odds ratio; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid refractory.

References: 1. Zeiser R, Polverelli N, Ram R, et al; for the REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft‑versus‑host disease. N Engl J Med. 2021;385(3):228-238. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2033122. 2. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation. 3. Data on file. Incyte Corporation. Wilmington, DE. 4. Zeiser R, Russo D, Ram R, et al. Ruxolitinib in patients with chronic graft-versus-host disease: 3-year final analysis of efficacy and safety from the phase III REACH3 study. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Session 722. 5. Locatelli F; for the REACH3 Study Group. Ruxolitinib vs best available therapy in patients with steroid-refractory/dependent chronic graft-vs-host disease: subgroup analyses of overall response rate in the phase 3 REACH3 trial. Presented at: 47th Annual Meeting of the EBMT; March 14-17, 2021; Rome, Italy. 6. Zeiser R, Xue Z, Bhatt V, Galvin J, Locatelli F. Early versus late treatment with ruxolitinib in patients with steroid-refractory chronic graft-versus-host disease: a post hoc analysis from the randomized, phase 3 REACH3 study. Poster presented at: 64th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA.

 
 

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Thrombocytopenia, Anemia and Neutropenia

  • JAKAFI®/JAKAFI XR™ (ruxolitinib) can cause dose‑related effects of thrombocytopenia, anemia and neutropenia. Perform a pre‑treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting JAKAFI/JAKAFI XR. Platelet transfusions may be necessary.
  • Patients developing anemia may require blood transfusions and/or dose modifications of JAKAFI/JAKAFI XR.
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding JAKAFI/JAKAFI XR until recovery.

INDICATIONS AND USAGE

JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.

JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Risk of Infection

  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting JAKAFI/JAKAFI XR until active serious infections have resolved. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of infection and manage promptly.

Tuberculosis

  • Tuberculosis (TB) infection with JAKAFI/JAKAFI XR has been reported. Observe patients taking JAKAFI/JAKAFI XR for signs and symptoms of active TB and manage promptly. Prior to initiating, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting in patients with evidence of active or latent TB. Continuation during treatment of active TB should be based on the overall risk‑benefit determination.

Progressive Multifocal Leukoencephalopathy

  • Progressive multifocal leukoencephalopathy (PML) has occurred with JAKAFI/JAKAFI XR treatment. If PML is suspected, stop JAKAFI/JAKAFI XR and evaluate.

Herpes Zoster and Herpes Simplex

  • Herpes zoster infection, reactivation and/or dissemination has been reported in patients receiving JAKAFI/JAKAFI XR. Advise patients about early signs and symptoms of herpes zoster and seek treatment. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment.

Hepatitis B

  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections.

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

  • When discontinuing JAK‑Inhibitors, including JAKAFI/JAKAFI XR, myeloproliferative neoplasm‑related signs and symptoms may flare. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, disseminated intravascular coagulation (DIC), or multi‑organ failure. If any of these occur after discontinuation or while tapering JAKAFI/JAKAFI XR, evaluate and treat any intercurrent illness and consider restarting or increasing the dose. Instruct patients not to interrupt or discontinue JAKAFI/JAKAFI XR without consulting their physician. When discontinuing or interrupting JAKAFI/JAKAFI XR for reasons other than life‑threatening toxicities, consider gradual tapering rather than abrupt discontinuation.

Non‑Melanoma Skin Cancer (NMSC)

  • NMSC including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations.

Lipid Elevations

  • Treatment with JAKAFI/JAKAFI XR has been associated with increases in total cholesterol, low‑density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8‑12 weeks after initiation.

Major Adverse Cardiovascular Events (MACE)

  • Another JAK‑inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Thrombosis

  • Another JAK‑inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV), the rates of thromboembolic events were similar in JAKAFI/JAKAFI XR and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Secondary Malignancies

  • Another JAK‑inhibitor has increased the risk of lymphoma and other malignancies, excluding NMSC (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Patients who are current or past smokers are at additional increased risk.

Adverse Reactions

  • In myelofibrosis, the most common hematologic adverse reactions (incidence >20%) were thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache and diarrhea.
  • In polycythemia vera, the most common hematologic adverse reactions (incidence >20%) were thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache and diarrhea.
  • In acute graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >50%) were anemia, thrombocytopenia and neutropenia. The most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema.
  • In chronic graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >35%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥20%) were infections (pathogen not specified) and viral infections.

Drug Interactions

  • Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.

Pregnancy

  • Use during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking JAKAFI/JAKAFI XR should not breastfeed during treatment and for 2 weeks after the final dose.

Please see Full Prescribing Information for JAKAFI/JAKAFI XR.